Dear Editor,

We read with great interest the recent article "COVID-19 Infection in a Patient with End-Stage Kidney Disease" by Fu et al. \[[@B1]\]. Previous studies have reported that ∼10% of infected patients may develop acute kidney injury (AKI), which is a strong prognostic factor increasing risk of death \[[@B2], [@B3], [@B4]\]. We agree with the authors that SARS-CoV2 affects the kidney function and special care of renal function should be taken into account in COVID-19 patients. However, the current definition of AKI does not provide a measurement of loss of kidney function because serum creatinine level is not a sensitive marker of early tubular injury (elevation of serum creatinine requires damage/dysfunction of \>50% of the nephron mass), whereas biomarkers of tubular injury provide information on early kidney injury and response to noxious stimuli \[[@B5]\].

All COVID-19 infection patients without a prior history of chronic kidney disease included in our study (*n* = 32) were consecutively admitted to our hospital in February, who were confirmed, classified as 3 subtypes (common, severe, and critical), and discharged from our hospital based on the guidelines for the diagnosis and treatment of novel coronavirus disease (version 6) \[[@B6]\].

Most of these patients had mean levels of estimated glomerular filtration rate (eGFR) within the normal range, whereas 31.3% (*n* = 10) had proteinuria, 9.4% (*n* = 3) had macroalbuminuria, and 12.5% (*n* = 4) had microalbuminuria (Table [1](#T1){ref-type="table"}). The proportion of patients with increased urinary levels of β2-microglobulin (β2MG), α1-microglobulin (α1MG), retinol binding protein (RBP), and *N*-acetyl-β-d-glucosaminidase (NAG) levels were 20, 20, 10, and 10%, respectively. On the first day of hospital admission, there were no significant differences in mean levels of serum creatinine, blood urea nitrogen, and eGFR among the common, severe, and critical subtypes. However, the proportion of albuminuria as well as the levels of urinary β2MG-creatinine ratio, α1MG-creatinine ratio, RBP-creatinine ratio, and NAG-creatinine ratio significantly increased according to the severity of disease. During the hospital stay, the proportion of proteinuria (dipstick \>1+) in critically ill COVID-19 patients was significantly higher than that observed in common COVID-19 patients on the first check and gradually improved during the patients\' hospital admission (Fig. [1](#F1){ref-type="fig"}). No significant differences were observed in the mean levels of eGFR both on the first day of admission and during the hospital stay amongst the 3 patient subtypes. Furthermore, Kaplan-Meier survival curves showed that patients with elevated urinary β2MG and α1MG levels had significantly lower rates of hospital discharge compared to those with normal urinary β2MG and α1MG levels.

In conclusion, we suggest that COVID-19 infection may induce early development of abnormal albuminuria and impair kidney tubular function. Because SARS-CoV-2 has been isolated from urinary samples of an infected patient and the receptor of this virus is the angiotensin converting enzyme II which is expressed on podocytes and proximal straight tubule cells \[[@B4], [@B7]\]. Notably, podocytes and proximal straight tubule cells are particularly vulnerable to viral attacks, and our findings suggested that the excretion of these urinary biomarkers may be related to the severity of the infection. Therefore, more careful medical surveillance of urinary biomarkers of early AKI is required in COVID-19-infected patients because early detection and treatment can slow or prevent progression of kidney disease.
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Baseline characteristics of patients with COVID-19 infection

                                          All patients       Disease subtypes                                                                                                                                        
  --------------------------------------- ------------------ ------------------ ---------------------------------------------- ------------------------------------------------------------------------------------- ---------
  Demographic parameters                                                                                                                                                                                             
   Age                                    61 (54--73)        61 (55--73)        64 (55--72)                                    55 (53--81)                                                                           0.957
   Male sex, *n* (%)                      20 (62.5)          3 (60)             10 (55.6)                                      7 (77.8)                                                                              0.608
  Clinical parameters                                                                                                                                                                                                
   Fever, *n* (%)                         17 (53.1)          1 (20)             12 (66.7)                                      4 (44.4)                                                                              0.159
   Heart rate, beats per minute           82 (76--94)        82 (72--87)        85 (76--96)                                    79 (68--94)                                                                           0.692
   Respiratory rate, breaths per minute   20 (20--22)        20 (18--20)        20 (20--23)                                    21 (19--33)                                                                           0.155
   Systolic blood pressure, mm Hg         136 (124--144)     138 (132--157)     129.5 (119--144)                               139 (130--167)                                                                        0.102
   Diastolic blood pressure, mm Hg        79 (72--82)        82 (75--88)        75 (68--82)                                    82 (74--87)                                                                           0.091
   Hypertension, *n* (%)                  10 (31.3)          2 (40)             5 (27.8)                                       3 (33.3)                                                                              0.879
   Diabetes, *n* (%)                      5 (15.6)           1 (20)             3 (16.7)                                       1 (11.1)                                                                              1,000
   CRRT, *n* (%)                          1 (3.1)            0                  0                                              1 (11.1)                                                                              0.438
   Invasive ventilation, *n* (%)          9 (28.1)           0                  1 (5.6)                                        8 (88.9)[^b^](#T1F2){ref-type="table-fn"}, [^c^](#T1F3){ref-type="table-fn"}          \<0.001
   ECMO, *n* (%)                          4 (12.5)           0                  0                                              4 (44.4)[^c^](#T1F3){ref-type="table-fn"}                                             0.006
  Length of hospital stay, days           23 (17--27)        14 (11--15)        22 (18--26)[^a^](#T1F1){ref-type="table-fn"}   27 (24--35)[^b^](#T1F2){ref-type="table-fn"}, [^c^](#T1F3){ref-type="table-fn"}       \<0.001
  Laboratory parameters                                                                                                                                                                                              
   Leukocyte count, ×10^9^/L              7.7 (5.7--11.8)    5.9 (5.5--12.7)    7.2 (5.2--11.4)                                8.2 (7.5--12.1)                                                                       0.466
   Lymphocyte count, ×10^9^/L             0.8±0.4            0.9±0.4            0.9±0.3                                        0.6±0.4                                                                               0.183
   Hemoglobin, g/L                        124.6±17.4         117.4±16.9         123.9±16.2                                     130±20.2                                                                              0.431
   Platelet count, ×10^9^/L               229.4±100.3        353.0±109.7        226.8±80.1[^a^](#T1F1){ref-type="table-fn"}    166.1±72.7[^b^](#T1F2){ref-type="table-fn"}                                           0.002
   C-reactive protein ≥10 mg/L, *n* (%)   29 (90.6)          4 (80)             16 (88.9)                                      9 (100)                                                                               0.395
   Alanine aminotransferase, U/L          24 (20--42)        39 (20--85)        23.5 (19--27)                                  42 (22--102)                                                                          0.197
   Aspartate aminotransferase, U/L        31 (25--61)        28 (21--48)        30 (25--35)                                    57 (39--96)[^c^](#T1F3){ref-type="table-fn"}                                          0.008
   Lactose dehydrogenase, U/L             401±151            257±77             365±103                                        553±145[^b^](#T1F2){ref-type="table-fn"}, [^c^](#T1F3){ref-type="table-fn"}           \<0.001
   Creatinine kinase, U/L                 70 (56--207)       64 (41--75)        64 (54--172)                                   164 (72--361)                                                                         0.037
   Serum albumin, g/L                     31.6 (29--35)      32.7 (29--37)      31.6 (29--35)                                  30.5 (29--33)                                                                         0.618
   Blood urea nitrogen, mg/dL             15.6±6.7           17.6±5.7           14.3±7.9                                       17.1±3.8                                                                              0.475
   Serum creatinine, mg/dL                0.7±0.1            0.8±0.1            0.7±0.2                                        0.8±0.1                                                                               0.566
   eGFR, mL/min/1.73 m^2^                 100.7±20.3         99.8±18.3          103.1±21.7                                     96.4±20.0                                                                             0.731
   Urinary β2MG ≥0.195 µg/mL, *n* (%)     20 (62.5)          2 (40)             11 (61.1)                                      7 (77.8)                                                                              0.417
   Urinary α1MG ≥12 mg/L, *n* (%)         20 (62.5)          1 (20)             12 (66.7)                                      7 (77.8)                                                                              0.086
   Urinary RBP ≥0.7 µg/mL, *n* (%)        10 (31.3)          0                  4 (22.2)                                       6 (66.7)                                                                              0.019
   Urinary NAG ≥14.6 U/L, *n* (%)         10 (31.3)          1 (20)             4 (22.2)                                       5 (55.6)                                                                              0.191
   Urinary β2MG-creatinine ratio, mg/g    0.4 (0.1--2.1)     0.2 (0.1--0.5)     0.2 (0.1--1.0)                                 4.8 (0.4--150)[^c^](#T1F3){ref-type="table-fn"}                                       0.024
   Urinary α1MG-creatinine ratio, mg/g    16.3 (8.1--37.6)   7.8 (3.7--15.9)    14.2 (7.5--28.8)                               222 (26.6--593)[^b^](#T1F2){ref-type="table-fn"}, [^c^](#T1F3){ref-type="table-fn"}   0.001
   Urinary RBP-creatinine ratio, mg/g     0.4 (0.2--4.7)     0.1 (0.1--0.3)     0.3 (0.2--0.6)                                 24.3 (0.5--166)[^b^](#T1F2){ref-type="table-fn"}, [^c^](#T1F3){ref-type="table-fn"}   0.001
   Urinary NAG-creatinine ratio, mg/g     8.1 (4.6--17.0)    6.6 (4.5--8.4)     7.5 (4.6--13.8)                                68.1 (6.1--172)[^c^](#T1F3){ref-type="table-fn"}                                      0.049
   Urinary ACR category, *n* (%)                                                                                                                                                                                     0.002
    ACR ≥30 mg/g                          7 (21.9)           0                  1 (5.6)                                        6 (66.7)                                                                              
    ACR \<30 mg/g                         25 (78.1)          5 (100)            17 (94.4)                                      3 (33.3)                                                                              
   Proteinuria, *n* (%)                                                                                                                                                                                              0.019
    Negative                              22 (68.8)          5 (100)            14 (77.8)                                      3 (33.3)                                                                              
    Positive                              10 (31.2)          0                  4 (22.2)                                       6 (66.7)                                                                              
  Clinical outcome                                                                                                                                                                                                   
    Remained in hospital, *n* (%)         12 (37.5)          0                  6 (33.3)                                       6 (66.7)                                                                              0.036
    Discharged, *n* (%)                   20 (62.5)          5 (100)            12 (66.7)                                      3 (33.3)                                                                              

Data are expressed as numbers (percentages) for categorical variables, means±SD for normally distributed continuous variables, and medians (interquartile ranges) for skewed distributed continuous variables. Differences between the groups were tested either by one-way ANOVA analysis (Bonferroni correction for comparisons) and the Kruskal-Wallis test (for continuous variables) or by the χ^2^ test and Fisher\'s exact test (for categorical variables). ACR, albumin to creatinine ratio; CRRT, continuous renal replacement therapy; eGFR, estimated glomerular filtration rate; ECMO, extracorporeal membrane oxygenation; RBP, retinol binding protein; NAG, *N*-acetyl-β-D-glucosaminidase; β2MG, β2-microglobulin; α1MG, α1-microglobulin.

*p* \< 0.05 between common and severe subtype.

*p* \< 0.05 between common and critical subtype.

*p* \< 0.05 between severe and critical subtype.

[^1]: Dan-Qin Sun and Ting-Yao Wang are co-first authors.
